A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2017
The purpose of this study is to initially access the safety and effectivity of RC18 combined with methotrexate (MTX) in comparison with the use of methotrexate alone in participants with moderate to severe Rheumatoid Arthritis (RA) who have an inadequate response to MTX therapy.
Epistemonikos ID: 46bc72b88601e107b652de3f5e8bbf1f97e28797
First added on: Mar 23, 2022